Katie Hoffman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katie Hoffman has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Carolyn Kelley
Children's Hospital Colorado
2 shared publications- Kristin J. Krosschell
Northwestern University Feinberg School of Medicine
2 shared publications - Laurey Brown
Ann and Robert H. Lurie Children's Hospital of Chicago
2 shared publications - Meghan Moore Burk
Children's Hospital Colorado
2 shared publications Vamshi Rao
Ann & Robert H Lurie Children's Hospital
2 shared publications- Abigail Schwaede
Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine Chicago Illinois USA
1 shared publication
Latest Publications
- Open Access
- 7 April 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (6) , 1334-1349
Navigating new motor function trajectories: Consensus recommendations for assessment in the era of newborn screening and early treatment in SMA
Background: Approved disease modifying treatments (DMTs) and the implementation of newborn screening for spinal muscular atrophy (SMA) have allowed individuals treated early to gain new motor abilities and achieve more typical motor milestones. In this changing landscape, current motor function outcome measures (MF-OMs) used in SMA clinical practice may no longer be sufficiently sensitive enough to optimally quantify new disease trajectories and evolving functional progression. Objective: To develop a consensus-derived recommendation for MF-OMs to be used in assessing infants and children living with SMA who were treated with DMTs very early in life. Methods: A modified Delphi methodology which included three web-based surveys and virtual conferences was conducted with an international group of multidisciplinary experts treating infants and children living with SMA who were treated early. Community input was also collected via semi-structured interviews. Results: A consensus-derived recommendation for MF-OMs to be routinely administered in early treated infants and children living with SMA was developed. Consensus recommendations included both SMA-specific and non SMA-specific MF-OMs for five age periods. MF-OMs were inclusive of Clinician-Reported, Caregiver/Patient-Reported, and Performance/Functional Outcome Measures. Recommendations on optimal assessment frequency varied across age periods from quarterly to bi-annually. Conclusions: Clinicians with expertise in SMA achieved consensus on establishing relevant MF-OMs to implement from infancy through childhood to track motor progress in early treated infants. Routine data collection using recommended MF-OMs will facilitate cohort comparison for research collaborations to better understand new disease trajectories and motor progression of this population.
- 7 April 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (6) , 1334-1349
Open AccessNavigating new motor function trajectories: Consensus recommendations for assessment in the era of newborn screening and early treatment in SMA
Background: Approved disease modifying treatments (DMTs) and the implementation of newborn screening for spinal muscular atrophy (SMA) have allowed individuals treated early to gain new motor abilities and achieve more typical motor milestones. In this changing landscape, current motor function outcome measures (MF-OMs) used in SMA clinical practice may no longer be sufficiently sensitive enough to optimally quantify new disease trajectories and evolving functional progression. Objective: To develop a consensus-derived recommendation for MF-OMs to be used in assessing infants and children living with SMA who were treated with DMTs very early in life. Methods: A modified Delphi methodology which included three web-based surveys and virtual conferences was conducted with an international group of multidisciplinary experts treating infants and children living with SMA who were treated early. Community input was also collected via semi-structured interviews. Results: A consensus-derived recommendation for MF-OMs to be routinely administered in early treated infants and children living with SMA was developed. Consensus recommendations included both SMA-specific and non SMA-specific MF-OMs for five age periods. MF-OMs were inclusive of Clinician-Reported, Caregiver/Patient-Reported, and Performance/Functional Outcome Measures. Recommendations on optimal assessment frequency varied across age periods from quarterly to bi-annually. Conclusions: Clinicians with expertise in SMA achieved consensus on establishing relevant MF-OMs to implement from infancy through childhood to track motor progress in early treated infants. Routine data collection using recommended MF-OMs will facilitate cohort comparison for research collaborations to better understand new disease trajectories and motor progression of this population.
- Open Access
- 30 December 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (4) , 748-768
New SMA era: A broad-range tiered assessment of function for the evolving SMA phenotype (EVOLVE-SMA)
Background: The clinical course of Spinal Muscular Atrophy (SMA) has been transformed by new disease-modifying therapies (DMT). Before DMT, the clinical course of SMA was marked by an inflection point between developmental improvement and degenerative functional losses. The well-established SMA classification by “type” was based upon the age and functional level at which this inflection point manifested. Following DMT, the natural history of SMA has evolved. The evolution of the SMA clinical course following DMT thus necessitates an updated means to characterize individuals with SMA. Objective: To address both clinical and research needs, an updated assessment should target meaningful function; apply broadly across the range of SMA; maximize the granularity of functional tiers with minimal compromise of reliability; require minimal or no specific training; and be validated with measurable consistency between both naïve and experienced clinicians, and between these clinicians and members of the SMA community. Methods/Design: Development of the Functional Ability Scale for Evolving SMA (EVOLVE-SMA) proceeded as an iterative scale creation and refinement process using retrospective cohorts (for design, reliability, and validity) followed by prospective assessments of real-world feasibility and reliability. Results: Excellent interrater reliability (ICC >0.9, p < 0.001) was established between expert and novice clinicians (physician and physical therapist) and clinicians versus SMA community members. Conclusions: EVOLVE-SMA is a tiered evaluation of function applicable to the new DMT-treated era of SMA. It is a simple, granular, and reliable means to assess meaningful functions that will have value to research, resource allocation, and individual clinical care.
- 30 December 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (4) , 748-768
Open AccessNew SMA era: A broad-range tiered assessment of function for the evolving SMA phenotype (EVOLVE-SMA)
Background: The clinical course of Spinal Muscular Atrophy (SMA) has been transformed by new disease-modifying therapies (DMT). Before DMT, the clinical course of SMA was marked by an inflection point between developmental improvement and degenerative functional losses. The well-established SMA classification by “type” was based upon the age and functional level at which this inflection point manifested. Following DMT, the natural history of SMA has evolved. The evolution of the SMA clinical course following DMT thus necessitates an updated means to characterize individuals with SMA. Objective: To address both clinical and research needs, an updated assessment should target meaningful function; apply broadly across the range of SMA; maximize the granularity of functional tiers with minimal compromise of reliability; require minimal or no specific training; and be validated with measurable consistency between both naïve and experienced clinicians, and between these clinicians and members of the SMA community. Methods/Design: Development of the Functional Ability Scale for Evolving SMA (EVOLVE-SMA) proceeded as an iterative scale creation and refinement process using retrospective cohorts (for design, reliability, and validity) followed by prospective assessments of real-world feasibility and reliability. Results: Excellent interrater reliability (ICC >0.9, p < 0.001) was established between expert and novice clinicians (physician and physical therapist) and clinicians versus SMA community members. Conclusions: EVOLVE-SMA is a tiered evaluation of function applicable to the new DMT-treated era of SMA. It is a simple, granular, and reliable means to assess meaningful functions that will have value to research, resource allocation, and individual clinical care.